Protalix BioTherapeutics (PLX) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.33 +0.87%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
SFNC, CSBR, MAN, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
SFNC, CSBR, MAN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $17.67 million versus the consensus estimate of $17.79 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Frequency Electronics (FEIM) Misses Q4 EPS by 89c
- UBS Upgrades Schaeffler AG (SHA:GR) (SFFLY) to Neutral
- Kotak Downgrades HDFC Asset Management Co Ltd (HDFCAMC:IN) to Add (2)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
